ABCG42 Antibody

ABCG2 Overview

ABCG2, also known as the breast cancer resistance protein (BCRP), is an ATP-binding cassette transporter involved in multidrug resistance (MDR) in cancer and pharmacological barrier functions . It regulates the efflux of xenobiotics, chemotherapeutic agents, and endogenous substrates (e.g., uric acid) .

ABCG2 Antibody Applications

Antibodies targeting ABCG2 are pivotal for:

• Flow cytometry: Quantifying ABCG2 expression in erythrocytes and cancer cells .

• Immunohistochemistry (IHC): Detecting ABCG2 in tissue samples (e.g., placenta, cancer biopsies) .

• Drug resistance studies: Identifying ABCG2 overexpression in chemotherapy-resistant cancers .

Table 1: Key ABCG2 Antibodies and Their Uses

Research Findings on ABCG2 Expression

• Genetic Variants: The Q141K polymorphism reduces ABCG2 expression by ~50% in erythrocytes, impacting uric acid metabolism and drug pharmacokinetics .

• Cancer Resistance:

  • ABCG2 upregulation mediates resistance to CDK7 inhibitors (e.g., ICEC0942, THZ1) in breast cancer .

  • Overexpression in acute myeloid leukemia (AML) correlates with poor prognosis and daunorubicin resistance .

• Blood Group System: ABCG2 encodes the Junior (Jr) blood group antigen; Jr(a−) individuals lack functional ABCG2 .

Mechanistic Insights

• Substrate Specificity: Mutations at residue 482 (e.g., R482G/T) alter substrate affinity, enhancing efflux of anthracyclines (e.g., doxorubicin) .

• Modulation: ABCG2 inhibitors (e.g., novobiocin, KO-143) reverse drug resistance in vitro .

Clinical Implications

• Biomarker Potential: Erythrocyte ABCG2 levels may predict tissue-specific expression patterns and drug response .

• Therapeutic Targeting: Antibodies like BXP-34 enable personalized diagnostics for optimizing chemotherapy regimens .

Unresolved Questions

• The physiological role of ABCG2 in stem cell protection remains under investigation .

• Standardization of ABCG2 detection methods (e.g., mRNA vs. protein assays) is needed for clinical translation .